Selection of Optimal Therapeutic Modality for Early-Stage Extranodal Natural Killer T-Cell Lymphoma Patients under the Guidance of Single-Nucleotide Polymorphism Signature. Biomol Biomed 2022, 22 (2), 300-301. https://doi.org/10.17305/bjbms.2021.6419.